Shifting Medicine Forward

Drawing on a deep understanding of the underlying causes of some of the most challenging diseases, Ichnos Sciences is pursuing truly disease-centric therapies in oncology and autoimmune disease. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.

Our path toward disease-centric therapies

oncology
Compound Target Preclinical IND-Enabling phase 1 phase 2 phase 3
ISB 1342 CD38 x CD3 BEAT®
bispecific antibody
Relapsed/Refractory Multiple Myeloma (MM)
     
ISB 1908 CD38 x CD3 BEAT® bispecific antibody
Relapsed/Refractory Multiple Myeloma
2H 2020      
ISB 1909 BEAT® T-cell engager
1H 2021      
ISB 1442 CD38 x CD47 BEAT® bispecific antibody
Hematologic Malignancies
2H 2020      
ISB 1302 HER2 x CD3 BEAT®
bispecific antibody
Metastatic HER2 + Breast Cancer
     
ISC XXXXX HPK1 inhibitor small molecule
2H 2020      
oncology
Compound:
ISB 1342
Target:
CD38 x CD3 BEAT®
bispecific antibody
Indication:
Relapsed/Refractory Multiple Myeloma (MM)
Phase:
phase-1
Compound:
ISB 1908
Target:
CD38 x CD3 BEAT® bispecific antibody
Indication:
Relapsed/Refractory Multiple Myeloma
Phase:
preclinical
IND-Enabling:
2H 2020
Compound:
ISB 1909
Target:
BEAT® T-cell engager
Phase:
preclinical
IND-Enabling:
1H 2021
Compound:
ISB 1442
Target:
CD38 x CD47 BEAT® bispecific antibody
Indication:
Hematologic Malignancies
Phase:
preclinical
IND-Enabling:
2H 2020
Compound:
ISB 1302
Target:
HER2 x CD3 BEAT®
bispecific antibody
Indication:
Metastatic HER2 + Breast Cancer
Phase:
phase-1
Compound:
ISC XXXXX
Target:
HPK1 inhibitor small molecule
Phase:
preclinical
IND-Enabling:
2H 2020
autoimmune disease
Compound Target Preclinical IND-Enabling phase 1 phase 2 phase 3
ISB 830† OX40 antagonist monoclonal antibody
Atopic Dermatitis (AD)
     
ISB 880 IL-1RAP antagonist monoclonal antibody
Autoimmune Disease
2H 2020      
autoimmune disease
Compound:
ISB 830†
Target:
OX40 antagonist monoclonal antibody
Indication:
Atopic Dermatitis (AD)
Phase:
phase-2
Compound:
ISB 880
Target:
IL-1RAP antagonist monoclonal antibody
Indication:
Autoimmune Disease
Phase:
preclinical
IND-Enabling:
2H 2020
pain management
Compound Target Preclinical IND-Enabling phase 1 phase 2 phase 3
ISC 17536* TPRA1 antagonist small molecule
Diabetic Peripheral Neuropathy (DPN)
     
pain management
Compound:
ISC 17536*
Target:
TPRA1 antagonist small molecule
Indication:
Diabetic Peripheral Neuropathy (DPN)
Phase:
phase-2

†A US IND to conduct studies of ISB 830 in additional indications, including Rheumatoid Arthritis, is active. Options for future development, including potentially partnering with other companies, are under consideration.

*Ichnos Sciences will complete preclinical and clinical work required to start a randomized Phase 2b study of ISC 17536 and plans to out-license the compound to enable greater focus on oncology and autoimmune disease.

Note: Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.

View Career Opportunities

United States

Switzerland

The links above are provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.

X
Concerning Your Privacy
Access to an Ichnos Site may be monitored by Ichnos. If monitored, the requesting URLs, the machine originating the request and the time of the request are logged for access statistics and security purposes. Your use and access of an Ichnos Site constitutes your consent to such general monitoring. Please see the Ichnos Privacy Policy and Cookie Notice for details on how information from the Site may be gathered and used.